Literature DB >> 718133

Relationship of lymphocyte invasion and survival of brain tumor patients.

W H Brooks, W R Markesbery, G D Gupta, T L Roszman.   

Abstract

The length of survival of 149 patients harboring primary brain tumors was retrospectively correlated with the presence and location of lymphocytic infiltration. Mononuclear invasion of malignant gliomas confined to the perivascular spaces was the only histolgical finding that correlated significantly with survival. Patients with malignant gliomas containing perivascular infiltration live up to four months longer than those with no lymphocyte infiltration. The survival of patients with brain tumors who had lymphocyte invasion associated with areas of hemorrhage and necrosis beyond and separate from perivascular spaces was the same as far as for those with no lymphocyte involvement.

Entities:  

Mesh:

Year:  1978        PMID: 718133     DOI: 10.1002/ana.410040305

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  63 in total

Review 1.  All in the head: obstacles for immune rejection of brain tumours.

Authors:  Paul R Walker; Thomas Calzascia; Pierre-Yves Dietrich
Journal:  Immunology       Date:  2002-09       Impact factor: 7.397

2.  CD8+ T-cell infiltrate in newly diagnosed glioblastoma is associated with long-term survival.

Authors:  Isaac Yang; Tarik Tihan; Seunggu J Han; Margaret R Wrensch; John Wiencke; Michael E Sughrue; Andrew T Parsa
Journal:  J Clin Neurosci       Date:  2010-08-19       Impact factor: 1.961

Review 3.  PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma?

Authors:  Mustafa Khasraw; David A Reardon; Michael Weller; John H Sampson
Journal:  Clin Cancer Res       Date:  2020-06-11       Impact factor: 12.531

4.  An increase in CD4+CD25+FOXP3+ regulatory T cells in tumor-infiltrating lymphocytes of human glioblastoma multiforme.

Authors:  Abdeljabar El Andaloussi; Maciej S Lesniak
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

Review 5.  The neurobiology of gliomas: from cell biology to the development of therapeutic approaches.

Authors:  Manfred Westphal; Katrin Lamszus
Journal:  Nat Rev Neurosci       Date:  2011-08-03       Impact factor: 34.870

6.  Ex vivo expansion of tumor-draining lymph node cells using compounds which activate intracellular signal transduction. I. Characterization and in vivo anti-tumor activity of glioma-sensitized lymphocytes.

Authors:  N G Baldwin; C D Rice; T M Tuttle; H D Bear; J I Hirsch; R E Merchant
Journal:  J Neurooncol       Date:  1997-03       Impact factor: 4.130

7.  A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

Authors:  Donald M O'Rourke; MacLean P Nasrallah; Arati Desai; Jan J Melenhorst; Keith Mansfield; Jennifer J D Morrissette; Maria Martinez-Lage; Steven Brem; Eileen Maloney; Angela Shen; Randi Isaacs; Suyash Mohan; Gabriela Plesa; Simon F Lacey; Jean-Marc Navenot; Zhaohui Zheng; Bruce L Levine; Hideho Okada; Carl H June; Jennifer L Brogdon; Marcela V Maus
Journal:  Sci Transl Med       Date:  2017-07-19       Impact factor: 17.956

8.  Modulation of tissue-type plasminogen activator expression by platelet activating factor in human glioma cells.

Authors:  Takuya Akai; Kenji Niiya; Nobuo Sakuragawa; Hideaki Iizuka; Shunro Endo
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

9.  Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype.

Authors:  E A Grimm; J M Bruner; J Carinhas; J A Köppen; W G Loudon; L Owen-Schaub; P A Steck; R P Moser
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

10.  Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial.

Authors:  R E Merchant; D W McVicar; L H Merchant; H F Young
Journal:  J Neurooncol       Date:  1992-01       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.